Cell Signalling and Oncogenes Flashcards Preview

SSC- Biology of Cancer > Cell Signalling and Oncogenes > Flashcards

Flashcards in Cell Signalling and Oncogenes Deck (81)
Loading flashcards...
1
Q

What do cells respond to?

A

Specific chemicals that signal them to divide

2
Q

What do the pathways for cell signalling utilised by cells have in common?

A

They all display the same fundamental characteristics

3
Q

What do all signalling pathways involve?

A
  • Chemical messenger
  • Receptor
  • Cellular response
4
Q

What is signal transduction?

A

Essentially, the transmission of a signal from the outside of a cell to the nucleus

5
Q

What can the signal transduced from the outside of the cell to the inside result in?

A

Alterations in cell metabolism, gene transcription, and/or cell shape

6
Q

What does alteration in gene transcription lead to?

A

Changes in protein expression

7
Q

What are proto-oncogenes?

A

Genes coding for proteins that help regulate cell growth and differentiation

8
Q

In what physiological process are proto-oncogenes fundamental?

A

Homeostasis

9
Q

What happens to proto-oncogenes in malignancy?

A

They become activated to an oncogene due to mutations, or increased expression

10
Q

Where is oncogene activation an important mechanism?

A

In human cancers

11
Q

What are the types of mutations that can cause cancer?

A
  • Deletion
  • Insertion
  • Substitution
  • Amplification
  • Translocation
12
Q

What can be deleted in mutations?

A
  • Base pair(s)
  • Genes
  • Chromosomes
13
Q

What can be inserted in mutations?

A
  • Repeats of base pair(s)
  • Novel insertions
  • Viruses
14
Q

What can be substituted in mutations?

A

Base pairs .

15
Q

What can be amplified in mutations?

A
  • Genes
  • Regions
  • Chromosomes
16
Q

What can be translocated in mutations?

A

Chromosomes

17
Q

What kind of proteins are encoded for by oncogenes?

A
  • Growth factors
  • Growth factor receptors
  • Protein kinases/proteins that activate protein kinases
  • Proteins that control the cell cycle
  • Proteins that affect apoptosis
  • Transcription factors
18
Q

What do growth factors do?

A

Stimulate cells to divide

19
Q

Give an example of a growth factor

A

PDGF

20
Q

What do growth factor receptors do?

A

Transduce signals from the outside of the cell to the inside

21
Q

Give an example of a growth factor receptor

A

EGF receptor (erbB)

22
Q

Give two examples of protein kinases

A
  • Src
  • Ras
23
Q

Give an example of a protein that activates protein kinases

A

Raf

24
Q

Give an example of a protein that controls the cell cycle

A

Cyclin D

25
Q

Give an example of a protein that affects apoptosis

A

Bcl-2

26
Q

Give an example of a transcription factor

A

Myc

27
Q

What is the significance of Myc in malignancy?

A

It is one of the most commonly altered oncogenes

28
Q

What are the mechanisms of oncogene activation?

A
  • Insertional mutagenesis
  • Chromosomal translocation
  • Chromosomal amplification
  • Point mutation
  • Ras signalling
29
Q

What happens in insertional mutagenesis?

A

DNA viruses incorporate a viral oncogene, which is inserted into the host DNA

30
Q

Give two examples of viruses capable of insertional mutagenesis

A
  • Human papillomavirus 16/18
  • Hepatitis B
31
Q

What is human papillomavirus 16/18 associated with?

A

Cervical cancer

32
Q

What advancement has been made with HPV and cervical cancer?

A

There is now an immunisation, so hopefully it will get eradicated over time

33
Q

What is hepatitis B associated with?

A

Hepatocellular cancer

34
Q

Give two examples of cancers caused by chromosomal translocations?

A
  • Chronic myeloid leukaemia
  • Burkitt’s lymphoma
35
Q

What is the chromosomal translocation in chronic myeloid leukaemia?

A

9;22 - c-abl (9) is truncated onto bcr (22)

36
Q

What is the result of the chromosomal translocation in chronic myeloid leukaemia?

A

Fusion protein has abnormal tyrosine kinase activity

37
Q

What is chromosomal translocation in Burkitt’s lymphoma?

A

8;14 - c-myc (8) is translocated onto igh (14)

38
Q

What is the result of the chromosomal translocation in Burkitt’s lymphoma?

A

It produces a strong promoter leading to constitutive MYC expression

39
Q

What happens in chromosomal amplification?

A

Tumour genomic instability leads to amplification, and may lead to over-production of normal protein, as multiple copies of the same gene are being expressed

40
Q

What can activate Ras?

A

Different activating mutations at codons 12, 13, and 61

41
Q

What is the most commonly activated Ras oncogene?

A

Ki-ras

42
Q

How is Ras activated?

A

By receptor tyrosine kinases that sit on the inside of the membrane

43
Q

What kind of protein is Ras?

A

A GTP-binding monomeric switch protein

44
Q

When is Ras active?

A

When it is bound to GTP, and therefore inactive after GTP hydrolysis

45
Q

What is the action of Ras?

A

Activates the MAP kinase pathway

46
Q

What does the type of Ras mutation determine in colorectal cancer?

A

The prognosis

47
Q

What is the 2 year survival in colorectal cancer patients with mutant Ras compared to wild type Ras?

A

It is 49% in mutant ras, compared to 69% in wt ras

48
Q

What mutations were significantly associated with a high risk of recurrence of colorectal cancer?

A

12 TGT and 13 GAC

49
Q

What did the RASCAL study find that the presence of KRAS mutation was associated with?

A

An increased risk of recurrence and death

50
Q

How did the RASCAL II study results compare with RASCAL?

A

It confimed the findings, but only in Dukes C (stage 3) tumours

51
Q

What are the activating mutations in the RAS-MAPK, PI(3)K signalling network?

A
  • KRAS
  • PI3KCA
  • BRAF
52
Q

What do activating mutations in the RAS-MAPK, PI(3)K signalling network correlate with?

A

Poor survival in colon cancers

53
Q

What must the role of KRAS be interpreted in the context of?

A

Other molecular and signalling abnormalities

54
Q

What is any mutation in KRAS, BRAF, or PI3KCA associated with?

A

A shorter 3 year survival

55
Q

Where can a KRAS mutation status identify an increased risk of recurrence?

A

In lymph nodes of stage 2 patients

56
Q

Why is it difficult for pharmaceutical companies to block Ras?

A

Ras is involved in widespread functions in the human body, but only 1 amino acid is changed in the mutant form, and so its hard to target.

57
Q

Give an example of a physiological role of Ras

A

It is an important pathway for synaptic remodelling in the human brain

58
Q

What % of metastatic melanomas have a mutation in BRAF?

A

50%

59
Q

What are the BRAF mutations found in metastatic melanoma?

A

Around 80% are V600E, 16% are V600K, and 3% are V600R

60
Q

Are BRAF mutations found in benign nevi?

A

Yes

61
Q

What is vemurafenib?

A

A BRAF inhibitor developed by Plexicon and Genentech

62
Q

What were the results of clinical trials involving vemurafenib?

A
  1. In Phase I, 16 patients with stage 4 cancers were enrolled into the programme, and it increased median survival from 9 to 15 months
  2. In Phase II, 132 patients with stage 4 cancers were enrolled into the programme, and 53% of patients responded.
  3. In phase III, 375 patients with stage III or IV cancers were enrolled in the programme, which compared vemurafenib to decarbazine. The trial was stopped early, and decarbazine patients were moved to vemurafenib
63
Q

What is the problem with vemurafenib?

A

It improves the patient for a window, but then the patient relapses with resistant disease

64
Q

What gene is associated with human breast cancers?

A

Her-2 (human epidermal growth factor receptor 2)

65
Q

In what % of human breast cancers is her-2 amplified and over-expressed?

A

10-30%

66
Q

What is HER-2 amplification in breast cancer linked to?

A

Poor prognosis - marker of aggressive cancer

67
Q

How is HER-2 amplification in human breast cancers detected?

A

By FISH and immunohistochemistry

68
Q

How is HER-2 positive breast cancer treated?

A

With drugs that bind to the receptor and prevent growth

69
Q

What drugs are used in the targeted therapy of HER-2 positive breast cancer?

A
  • Trastuzumab (Herceptin)
  • Pertuzumab (Perjeta)
  • Ado-trastuzumab emtansine (Kadcyla)
  • Lapatinib (Tykerb)
70
Q

What kind of drug is herceptin?

A

Monoclonal antibodies

71
Q

What is herceptin often used with?

A

Chemotherapy, but it can be used by itself

72
Q

What is herceptin used to treat?

A

Early- and late-stage breast cancer

73
Q

How long would a patient typically take herceptin for after surgery?

A

12 months

74
Q

What kind of drug is perjeta?

A

Monoclonal antibody

75
Q

What can perjeta be given with?

A

Trastuzumab and chemo

76
Q

When is perjeta given?

A

Either before surgery to treat early-stage breast cancer, or to treat advanced trastuzumab in chemo

77
Q

What kind of drug is Kadcycla?

A

A monoclonal antibody attached to a chemotherapy drug

78
Q

What is kadcycla used to treat?

A

Advanced breast cancer in women who have already been treated with trastuzumab and chemo

79
Q

What kind of drug is Tykerb?

A

A kinase inhibitor

80
Q

What is tykerb used to treat?

A

Advanced breast cancer, most often when trastuzumab is no longer working

81
Q

What is tykerb typically used with?

A

Certain chemotherapy or hormone therapy drugs